MedPath

Assessment of plasma dexamethasone level after 1-mg dexamethasone suppression test in adults with obesity

Phase 1
Completed
Conditions
compared the plasma dexamethasone levels after 1-mg DST in healthy obese participants and in normal-weight participants.
Plasma dexamethasone, Dexamethasone levels, 1-mg dexamethasone suppression test, Obesity
Registration Number
TCTR20220223003
Lead Sponsor
Ratchadapisek Research Funds
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
92
Inclusion Criteria

participants aged more than 18 years

Exclusion Criteria

-pregnancy, diabetes mellitus, known CS, psychiatric disease, chronic liver disease, chronic renal failure stage 3 to 5, nephrotic syndrome, malabsorption disease
-Heavy alcohol drinking more than 30 gm/day
-taking drugs that interfering CYP3A4 within 1 month or oral contraceptives within 6 weeks prior to the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Compare plasma dexamethasone levels after 1-mg DST in obese participants and in normal-weight participants 12 mo LC-MS/MS
Secondary Outcome Measures
NameTimeMethod
Association of Sex, BMI, BSA and dexamethasone level 12 mo LC-MS/MS,proportion of participants achieving the plasma dexamethasone levels more than 3.3 nmol/L among the BMI groups 12 mo LC-MS/MS
© Copyright 2025. All Rights Reserved by MedPath